Company profile
Shanghai Cell Therapy Group Co., Ltd.
Privately held: no public share price (Privately-held Chinese CAR-T biopharma (Shanghai), raised CNY 650M Series C2 plus >CNY 2B total from investors including Legend Capital and Haier Capital; no public listing found (EqualOcean, Crunchbase, Synapse). Sources: https://clinicaltrials.gov/study/NCT06732232 Entity resolved by asset-pipeline-v2.)
Assets
(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | CD19, CD22, and BCMA (tri-antigen) | Systemic Lupus Erythematosus | |
| Phase 1 | CD19, CD20, and BCMA (tri-target)Cell therapy | Multiple Myeloma |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.